CatalYm

Active#34 in Germany

Cancer immunotherapy

Biotech›cancer immunotherapy

Founded2016

HQPlanegg-Martinsried (Munich)

RaisedUSD 150M+

Last roundSeries D · Jul 2024

Country of originGermanyListed in the Germany ranking

Where would you invest?GermanyJurisdiction as cited by the ranking

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
Germany · all sectors	Top 50	#34	Edition 0 – beta · October 2026	11 Oct 2026

Rank historyOct 2026 · #34First edition: no movements yet.

Estimated valuation

AI · Germany ranking

≈ USD 770MUSD 520M–1.2bn · Hundreds of M$ Medium confidence

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Hectocorn

Anchor: Last known equity round: Series D · USD 150M · Jul 2024
AI adjustment: None

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

USD 150M+ raised in total

Date	Round	Amount	Type	Investors
Jul 2024	Series D	USD 150M	Equity	Canaan, Bayer, Novo Holdings

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of CatalYm as a PDF, on one of three angles only:

ValuationWhat is CatalYm worth?

Versus competitorsIs #34 the right rank?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back CatalYm whether or not it has agreed: your intention joins the pool on CatalYm, passed to the local partner once it reaches critical mass. Declaring an intention does not mean this company is raising funds.

Back CatalYm Or back biotech in Germany

Pool on CatalYmBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until a deal process opens. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run CatalYm?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in Germany

Full Germany ranking →

Tubulis#17Biotech › antibody-drug conjugatesUnicorn SciRhom#50Biotech › antibodies for autoimmune diseaseHundreds of M$AMBOSS#33Healthtech › clinical knowledge platformHundreds of M$commercetools#35Software › composable commerceHundreds of M$

Investors in CatalYm: Canaan · Bayer · Novo Holdings

Last updated: Oct 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.